Efficacy of molecular adsorbent recirculating system albumin dialysis in the treatment of hepatic encephalopathy associated with liver failure: a meta-analysis.
Weiying Xiang, Lei Zhang, Zhan Zhang
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis evaluated the efficacy and safety of the molecular adsorbent recirculating system (MARS) in treating hepatic encephalopathy due to liver failure. Seven studies were included, revealing that MARS significantly improved hemoglobin (SMD: -0.81), creatinine (SMD: -0.46), and INR (SMD: -0.22), while not significantly affecting albumin or bilirubin levels. No increased risk of bleeding or infection was observed.
Key findings
- MARS significantly improved hemoglobin levels (SMD: -0.81, P = 0.01).
- Creatinine levels improved significantly with MARS treatment (SMD: -0.46, P < 0.0001).
- INR levels showed significant improvement (SMD: -0.22, P = 0.004).
- No significant increase in bleeding or infection risk was found (risk ratio: 1.23, P = 0.30).
Why it matters
Understanding the efficacy and safety of MARS in hepatic encephalopathy is crucial for clinicians managing liver failure patients. Improved biochemical markers may indicate better patient outcomes, although further high-quality studies are needed to confirm these findings.
What to keep in mind
The analysis included a limited number of studies with suboptimal quality and heterogeneity.